Automate Your Wheel Strategy on TIL
With Tiblio's Option Bot, you can configure your own wheel strategy including TIL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TIL
- Rev/Share 0.0
- Book/Share 22.1827
- PB 1.2555
- Debt/Equity 0.0
- CurrentRatio 0.0
- ROIC -0.7037
- MktCap 182694051.0
- FreeCF/Share -8.5258
- PFCF -3.2802
- PE -2.3315
- Debt/Assets 0.0
- DivYield 0
- ROE -0.4552
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | TIL | Jefferies | Hold | Buy | $11 | $52 | Jan. 7, 2025 |
News
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Instil Bio (TIL) points to a 246.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer. Dr. Freedman brings deep experience in oncology drug development and other therapeutic areas, and a track record of leading programs through all phases of development, regulatory approval and commercialization.
Read More
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Instil Bio (TIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 343.6% upside potential for Instil Bio (TIL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Phase 3 trial of ‘2510 in combination with chemotherapy in first-line NSCLC anticipated to start in mid-2026 in China, subject to regulatory discussions
Read More
About Instil Bio, Inc. (TIL)
- IPO Date 2021-03-19
- Website https://instilbio.com
- Industry Biotechnology
- CEO Mr. Bronson Crouch
- Employees 14